Pfizer’s Dalbavancin “Approvable”
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA issued an "approvable" letter for Pfizer's lipoglycopeptide antibiotic dalbavancin Sept. 21, the agency saidYou may also be interested in...
Pfizer Receives “Approvable” Letter For MRSA Antibiotic Dalbavancin
Pfizer Receives “Approvable” Letter For MRSA Antibiotic Dalbavancin
Pfizer “Approvable” Streak Continues With Second letter For Anidulafungin
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: